Hepatitis B vaccine recombinant - Changchun huapu biological technique/Zhejiang Provincial Center for Disease Control and Prevention

Drug Profile

Hepatitis B vaccine recombinant - Changchun huapu biological technique/Zhejiang Provincial Center for Disease Control and Prevention

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Changchun huapu biological technique; Zhejiang Provincial Center for Disease Control and Prevention
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 11 Jun 2017 Changchun huapu biological technique completes a phase I trial in Hepatitis B (In volunteers, Prevention) in China (ChiCTR-IIR16009836)
  • 12 Nov 2016 Phase-I clinical trials in Hepatitis B (In volunteers, Prevention) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top